MedTrace Logo

Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

NCT03269019 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-08-31

No results posted yet for this study

Summary

Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%. Early diagnosis of HIT and prevention of thrombosis is very important.

This study is planned to assess the use of thrombotic biomarkers in patients with HIT, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy monitoring . These biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in HIT patients. All patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.

Conditions

  • Heparin-Induced Thrombocytopenia
  • Thrombosis
  • Biomarkers

Interventions

DIAGNOSTIC_TEST

HIT with thrombosis

Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.

Sponsors & Collaborators

  • Wuhan Asia Heart Hospital

    lead OTHER

Principal Investigators

  • Zhenlu Zhang, MD,Ph.D · Wuhan Asia Heart Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-20
Primary Completion
2019-08-19
Completion
2019-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269019 on ClinicalTrials.gov